Characteristics and Treatment Response of Patients with HIV Associated Kaposi's Sarcoma in Central Kenya

被引:1
作者
McLigeyo, Angela [1 ]
Owuor, Kevin [1 ]
Ng'ang'a, Evelyne [1 ]
Mwangi, Jonathan [2 ]
Wekesa, Paul [1 ]
机构
[1] Ctr Hlth Solut Kenya, CVS Plaza,4th Floor,Kasuku Rd,Off Lenana Rd, Nairobi, Kenya
[2] Ctr Dis Control & Prevent CDC, Div Global HIV & TB, Nairobi, Kenya
来源
HIV AIDS-RESEARCH AND PALLIATIVE CARE | 2022年 / 14卷
关键词
HIV; Kaposi's sarcoma; characteristics; treatment; response; adults; ACTIVE ANTIRETROVIRAL THERAPY; INFECTED INDIVIDUALS; HERPESVIRUS; MEN; HUMAN-HERPESVIRUS-8; PREVALENCE; OUTCOMES; PATTERN; CANCER; HAART;
D O I
10.2147/HIV.S359278
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Kaposi's sarcoma (KS) is the most common HIV-associated malignancy in Sub Saharan Africa. In 2018, it was the 7th most common cancer and the 10th most common cause of cancer death in Kenya. This study aimed to describe the baseline and clinical characteristics and treatment response observed following combined antiretroviral treatment (ART) and chemotherapy in KS patients. Methods: This was a descriptive analysis of patients aged >= 15 years treated for KS and HIV at 11 treatment hubs in Central Kenya between 2011 and 2014. Data on baseline and clinical characteristics, ART and chemotherapy regimens as well as treatment responses were collected from patient files and KS registers. Results: A total of 95 patients presenting with clinically suspected KS with no history of prior treatment with chemotherapy were reviewed. All had histological diagnostic samples taken with 67 (71%) having confirmed KS. All were on ART, either newly initiated or continuing on ART, and 63 of the 67 (94.0%) confirmed to have KS received chemotherapy. Among the 67 patients with confirmed KS, mean age was 37.2 years (+/- 13.2) and 40 (59.7%) were male. More than 80% had normal baseline and follow-up BMI, and 34 (50.7%) were on a TDF-based regimen, 52 (77.6%) were treated with the Adriamycin, bleomycin and vinblastine protocol, and 55 (82.1%) had KS diagnosis before HIV diagnosis. All 67 patients had mucocutaneous lesions. Complete, partial response and stable disease occurred in 27 (40.3%), 10 (14.9%) and 7 (10.4%), respectively, 11 (16.4%) defaulted care during treatment, six patients died during treatment, four patients died before treatment while two patients had progressive disease during chemotherapy. Conclusion: The diagnosis of KS preceded HIV in the majority of cases reviewed, with histology helpful to reduce misdiagnosis. Patients generally complied with their chemotherapy, with overall good response rate for this intervention implemented at primary health-care facilities.
引用
收藏
页码:207 / 215
页数:9
相关论文
共 50 条
  • [41] Oncologic Treatment of HIV-Associated Kaposi sarcoma 40 Years on
    Ramaswami, Ramya
    Lurain, Kathryn
    Yarchoan, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (03) : 294 - +
  • [42] Chemotherapy in HIV-infected patients with Kaposi's sarcoma
    Pechère, M
    Krischer, J
    Rutschmann, OT
    DERMATOLOGY, 1997, 195 (04) : 411 - 411
  • [43] Do fewer cases of Kaposi's sarcoma in HIV-infected patients reflect a decrease in HHV8 seroprevalence?
    Reinheimer, Claudia
    Allwinn, Regina
    Stuermer, Martin
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2011, 200 (03) : 161 - 164
  • [44] Menetrier's Disease associated with Kaposi's Sarcoma
    diSibio, Guy
    McPhaul, Laron W.
    Sarkisian, Armine
    Van Pham, Binh
    French, Samuel W.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2008, 85 (03) : 160 - 164
  • [45] Real-world use of chemotherapy for Kaposi's sarcoma in a large community-based HIV primary care system in Kenya
    Freeman, Esther E.
    Busakhala, Naftali
    Regan, Susan
    Asirwa, Fredrick Chite
    Wenger, Megan
    Seth, Divya
    Moon, Khatiya Chelidze
    Semeere, Aggrey
    Maurer, Toby
    Wools-Kaloustian, Kara
    Bassett, Ingrid
    Martin, Jeffrey
    BMC CANCER, 2020, 20 (01)
  • [46] Evaluation of four chemotherapy regimens for treatment of advanced AIDS-associated Kaposi sarcoma in Kenya: a cost-effectiveness analysis
    Freeman, Esther E.
    McCann, Nicole C.
    Semeere, Aggrey
    Reddy, Krishna P.
    Laker-Oketta, Miriam
    Byakwaga, Helen
    Pei, Pamela P.
    Fernandez, Maya E. Hajny
    Kiprono, Samson
    Busakhala, Naftali
    Martin, Jeffery N.
    Maurer, Toby
    Bassett, Ingrid, V
    Freedberg, Kenneth A.
    Hyle, Emily P.
    LANCET GLOBAL HEALTH, 2022, 10 (08): : E1179 - E1188
  • [47] Infection with Kaposi's sarcoma-associated herpesvirus (KSHV) and human immunodeficiency virus (HIV) in relation to the risk and clinical presentation of Kaposi's sarcoma in Uganda
    Newton, R
    Ziegler, J
    Bourboulia, D
    Casabonne, D
    Beral, V
    Mbidde, E
    Carpenter, L
    Parkin, DM
    Wabinga, H
    Mbulaiteye, S
    Jaffe, H
    Weiss, R
    Boshoff, C
    BRITISH JOURNAL OF CANCER, 2003, 89 (03) : 502 - 504
  • [48] Association of Kaposi's sarcoma associated herpesvirus (KSHV) DNA in bronchoalveolar lavage fluid of HIV infected individuals with bronchoscopically diagnosed tracheobronchial Kaposi's sarcoma
    Howard, MR
    Brink, NS
    Whitby, D
    Tedder, RS
    Miller, RF
    SEXUALLY TRANSMITTED INFECTIONS, 1998, 74 (01) : 27 - 31
  • [49] Infection with Kaposi's sarcoma-associated herpesvirus (KSHV) and human immunodeficiency virus (HIV) in relation to the risk and clinical presentation of Kaposi's sarcoma in Uganda
    R Newton
    J Ziegler
    D Bourboulia
    D Casabonne
    V Beral
    E Mbidde
    L Carpenter
    D M Parkin
    H Wabinga
    S Mbulaiteye
    H Jaffe
    R Weiss
    C Boshoff
    British Journal of Cancer, 2003, 89 : 502 - 504
  • [50] Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy
    V Martinez
    E Caumes
    L Gambotti
    H Ittah
    J-P Morini
    J Deleuze
    I Gorin
    C Katlama
    F Bricaire
    N Dupin
    British Journal of Cancer, 2006, 94 : 1000 - 1006